# US 2026/0076912 A1 · Pharmaceutical compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076912 A1
- Document ID: US20260076912A1
- Status: Published application
- Kind: A1
- Application number: 19/326,549
- Filed: 2025-09-11
- Published: 2026-03-19
- Earliest claimed: 2024-09-13
- Assignees: Douglas Pharmaceuticals Limited
- Applicants: Douglas Pharmaceuticals Ltd
- Inventors: Peter William Surman; Zhen Shi; Fergus Cameron Binnie
- Web page: https://patentgrep.com/patent/US20260076912A1

## CPC

- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2095: {Tabletting processes}
- A61K 9/282: {Organic compounds, e.g. fats}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2893: {Tablet coating processes (mechanical aspects A61J3/06)}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described is an extended release pharmaceutical composition. The composition comprises a therapeutically effective amount of an active agent selected from the group consisting of ketamine, norketamine, pharmaceutically acceptable salts thereof, and combinations thereof. The active agent is incorporated into a sustained-release polymeric matrix. The matrix comprises a matrix polymer, and a permeability-modifying filler. A method of preventing, treating and/or managing treatment-resistant depression in a subject is also or alternatively describe.

## Claims

### Claim 1

An extended release pharmaceutical composition comprising:
a therapeutically effective amount of an active agent selected from the group consisting of ketamine, norketamine, pharmaceutically acceptable salts thereof, and combinations thereof,
wherein the active agent is incorporated into a sustained-release polymeric matrix, the matrix comprising:
a matrix polymer, and
a permeability-modifying filler.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the matrix comprises about 30 to 75% w/w of the matrix polymer and about 20 to 60% w/w of the permeability-modifying filler.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the permeability-modifying filler is slightly soluble, very slightly soluble, practically insoluble, or insoluble in water at about 20° C.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition comprises about 12 to 30% w/w of the active agent.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the pharmaceutical composition is a tablet comprising about 50 to 80 mg of ketamine.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the matrix polymer is selected from one or more of the group hydroxypropyl methylcellulose, a carbomer homopolymer, and hydroxypropylcellulose.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the ratio of the active agent to the matrix polymer is about 1:1.5 to 1:4.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the permeability-modifying filler is selected from one or more of microcrystalline cellulose, starch (for example, without limitation, corn starch, pea starch, potato starch, rice starch, tapioca starch, wheat starch, arrowroot starch), calcium carbonate, and dicalcium phosphate.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the composition exhibits an in vitro release with at least three of the following:
(a) about 25 to 35% of the active substance is released at about the 1 hour time point;
(b) about 36 to 50% of the active substance is released at about the 2 hour time point;
(c) about 53 to 73% of the active substance is released at about the 4 hour time point;
(d) about 64 to 88% of the active substance is released at about the 6 hour time point;
(e) about 73 to 99% of the active substance is released at about the 8 hour time point;
(f) about 79 to 100% of the active substance is released at about the 10 hour time point;
(g) about 81 to 100% of the active substance is released at about the 12 hour time point;
when tested according to the USP Apparatus 1 (basket) method at a rotation rate of 100 rpm in media at pH 1.0 at 37.0±0.5° C.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the composition exhibits an in vitro release of:
about 31 to 44 mg of ketamine at 4 hours, and
about 48 to 60 mg of ketamine at 12 hours
when tested according to the USP Apparatus 1 (basket) method at a rotation rate of 100 rpm in media at pH 1.0 at 37.0±0.5° C.,
wherein the extended release pharmaceutical composition is a tablet comprising about 60 mg of ketamine.

### Claim 11 (depends on 1)

The composition of claim 1, wherein administration of the extended release pharmaceutical composition to a subject providing a dose of about 180 mg of ketamine results in a ketamine plasma concentration profile AUC of about 270 to 370 ng·hr/ml

### Claim 12 (depends on 1)

The composition of claim 1, wherein administration of the extended release pharmaceutical composition to a subject providing a dose of about 180 mg of ketamine results in a norketamine plasma concentration profile AUC of about 3000 to 4000 ng·hr/ml.

### Claim 13 (depends on 1)

The composition of claim 1, wherein administration of the extended release pharmaceutical composition to a subject providing a dose of about 180 mg of ketamine results in a ketamine plasma concentration profile Cmax of about 20 to 50 ng/ml.

### Claim 14 (depends on 1)

The composition of claim 1, wherein administration of the extended release pharmaceutical composition to a subject providing a dose of about 180 mg of ketamine results in a norketamine plasma concentration profile Cmax of about 250 to 320 ng/ml.

### Claim 15 (depends on 1)

The composition of claim 1, wherein administration of the extended release pharmaceutical composition to a subject providing a dose of about 180 mg of ketamine results in a plasma concentration profile with a ratio of AUC norketamine/ketamine of about 8 to 15.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the extended release pharmaceutical composition comprises about 90 to 110% of a starting amount of the active agent after 24 months of storage at 25° C. with 60% relative humidity.

### Claim 17 (depends on 1)

The composition of claim 1, wherein the matrix comprises:
about 30 to 75% w/w of a matrix polymer,
about 20 to 60% w/w of a permeability-modifying filler,
wherein the permeability-modifying filler is slightly soluble, very slightly soluble, practically insoluble, or insoluble in water at about 20° C., and
wherein the pharmaceutical composition is a tablet with a mass of about 300 to 600 mg and/or the tablet comprises about 50 to 80 mg of ketamine.

### Claim 18 (depends on 1)

The composition of claim 1, wherein the matrix comprises:
about 45 to 80% w/w of a matrix polymer, and
about 3 to 35% w/w of a permeability-modifying filler,
wherein the permeability-modifying filler is very soluble or freely soluble in water at about 20° C., and
wherein the pharmaceutical composition is a tablet with a mass of about 300 to 600 mg and/or comprises about 50 to 80 mg of ketamine.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the matrix comprises:
about 20 to 45% w/w of a matrix polymer, and
about 40 to 65% w/w of a permeability-modifying filler,
wherein the pharmaceutical composition is a tablet with a mass of about 700 to 1000 mg and/or comprises about 100 to 140 mg of ketamine, and wherein the permeability-modifying filler is slightly soluble, very slightly soluble, practically insoluble, or insoluble in water at about 20° C.

### Claim 20

A method of preventing, treating and/or managing depression, anxiety, alcohol abuse disorder, and/or pain in a subject, the method comprising administering an extended release pharmaceutical composition, wherein the extended release pharmaceutical composition comprises:
a therapeutically effective amount of an active agent selected from the group consisting of ketamine, norketamine, pharmaceutically acceptable salts thereof, and combinations thereof,
wherein the active agent is incorporated into a sustained-release polymeric matrix, the matrix comprising:
a matrix polymer, and
a permeability-modifying filler.

### Claim 21

A method of manufacturing an extended release pharmaceutical composition, the method comprising:
blending a therapeutically effective amount of an active agent selected from the group consisting of ketamine, norketamine, pharmaceutically acceptable salts thereof, and combinations thereof, with a matrix polymer and a permeability-modifying filler.
